This cardiomyopathy is accompanied by an increase in the expression of CCR5 on the surface of circulating lymphocytes and the use of a partial CCR5 antagonist protected mice from cardiomyopathy [103]. This evidence concerns the gene CCR5 and cardiomyopathy.